Kura Oncology is a clinical-stage biopharmaceutical company whose mission is to realize the promise of precision medicines to help patients with cancer lead better, longer lives. We are advancing a number of precision medicines for the treatment of solid tumors and hematologic malignancies including ziftomenib (KO-539), a menin inhibitor, which is being studied in genetically defined subsets of patients that includes NPM1 mutant and KMT2A-rearranged acute myeloid leukemia.